How to Get Provigil (Modafinil) in Pennsylvania

Provigil, manufactured by Teva (formerly Cephalon), is the brand-name formulation of modafinil, a wakefulness-promoting agent. As a Schedule IV controlled substance, modafinil differs chemically from armodafinil (Nuvigil), its longer-acting enantiomer. The FDA has approved modafinil for treating narcolepsy, excessive daytime sleepiness in obstructive sleep apnea (when combined with primary OSA treatments like CPAP), and shift-work sleep disorder.

The direct answer: in Pennsylvania, any physician (MD/DO), and in many cases a nurse practitioner or physician assistant with appropriate prescribing authority, can prescribe modafinil after an in-person or telehealth evaluation confirming a qualifying diagnosis. Pennsylvania does not impose extra state-level licensing hurdles beyond federal DEA scheduling and the state's controlled-substance monitoring requirements. The practical barrier for most patients is not finding a willing prescriber, it is documentation: insurers generally require evidence of an on-label diagnosis before they will cover the drug, and off-label use (cognitive enhancement, general fatigue) is usually a cash-pay decision.

This article distinguishes what is established (FDA labeling, DEA scheduling, general Pennsylvania licensure structure) from what is plausible but state-and-plan-specific (exact insurer turnaround times, specific dollar prices, individual MCO forms), because those details change and were not independently verified for this draft.

Who can prescribe modafinil in Pennsylvania

Modafinil's federal Schedule IV status means Pennsylvania physicians licensed by the State Board of Medicine or Osteopathic Medicine can prescribe it without a specialist referral. Nurse practitioners and physician assistants may also have prescribing authority for Schedule IV medications, but the scope depends on their individual collaborative or supervising-physician agreement and on current Pennsylvania Board of Nursing and Board of Medicine rules. Because these scope-of-practice rules are periodically updated, a patient or clinician should confirm current authority directly with the relevant licensing board rather than relying on a fixed citation.

Prescribers of controlled substances in Pennsylvania are expected to check the state's Prescription Drug Monitoring Program before writing a new Schedule IV prescription. The exact workflow and turnaround differ by practice and were not verified for this article.

Does telehealth work for a modafinil prescription in Pennsylvania?

Pennsylvania permits telehealth prescribing of controlled substances, including Schedule IV drugs like modafinil, following a real-time audio-video evaluation. This is the main practical access point for patients outside major metro areas, since sleep medicine specialists are concentrated around Philadelphia, Pittsburgh, and a handful of other academic centers.

A telehealth visit does not remove the underlying clinical requirement: the prescriber still needs a sleep history, a plausible qualifying diagnosis, and (for narcolepsy specifically) typically a prior polysomnogram and multiple sleep latency test, per general sleep medicine practice. For shift-work sleep disorder, a documented shift schedule and persistent sleepiness or insomnia is usually sufficient without a sleep study. Individual platform turnaround times (same day versus several days) vary by clinician availability and are not a fixed, verifiable fact and should be confirmed with the specific service before assuming a timeline.

On-label versus off-label use: why this distinction drives coverage

This is the single most consequential decision point for Pennsylvania patients trying to get modafinil covered.

• On-label (narcolepsy, OSA-related residual sleepiness, shift-work sleep disorder): supported by the FDA label and generally eligible for insurance coverage with documentation.
• Off-label (ADHD, MS-related fatigue, depression-related fatigue, cognitive enhancement in healthy people): not an FDA-approved use. A narrative literature review has discussed neurostimulant agents, including modafinil-class drugs, in contexts such as stroke rehabilitation, but this reflects an active area of study rather than an approved indication, and the population studied (post-stroke patients) is different from most people seeking a Pennsylvania telehealth evaluation (Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review, 2025). Off-label prescribing is legal and sometimes clinically reasonable, but insurers routinely deny it, and patients pursuing it should expect to pay cash.

Academic health systems in Pennsylvania (large university-affiliated systems in Philadelphia and Pittsburgh, for example) tend to require a documented on-label indication for first prescriptions. Community and telehealth-based prescribers vary in their willingness to prescribe off-label when the clinical reasoning is documented in the chart. Neither approach is inherently wrong; the difference is risk tolerance and documentation practice, not a Pennsylvania-specific rule.

What insurance coverage in Pennsylvania actually requires

Pennsylvania Medicaid (Medical Assistance) has historically covered generic modafinil for narcolepsy and shift-work sleep disorder with prior authorization, generally requiring a confirmed diagnosis and documentation of prior conservative or behavioral treatment attempts. The specific managed care organization, required forms, decision-timeline rules, and appeal windows are plan- and date-specific. This draft does not carry forward the source's exact decision-timeline numbers because they were not independently verified against a current, citable Pennsylvania Department of Human Services or MCO document; a reader relying on a specific turnaround time should confirm it directly with their MCO before the article is published.

Commercial insurance coverage for generic modafinil also varies by plan design and tier placement. Brand-name Provigil is rarely stocked or covered given long-standing generic availability; a patient asking about "Provigil" at a Pennsylvania pharmacy will most often be dispensed generic modafinil unless brand is specifically requested and covered.

Cash-pay prices for generic modafinil change over time and by pharmacy and discount program. Any specific dollar figure quoted for Pennsylvania pharmacies should be treated as a snapshot that needs to be re-verified at the time a reader is deciding where to fill a prescription, not a fixed fact.

Pharmacies, mail order, and compounding

Standard retail and chain pharmacies with DEA registration and Pennsylvania Board of Pharmacy licensure can dispense generic modafinil; this is routine stock at large chains. Independent pharmacies may occasionally need to order it.

Mail-order pharmacy for Schedule IV medications is generally permitted, and multiple national mail-order pharmacies dispense to Pennsylvania addresses. Availability and pricing through any specific mail-order vendor should be confirmed at the time of ordering.

Some 503A compounding pharmacies can prepare modafinil in alternative dosage forms (for example, a liquid suspension) for a patient who cannot swallow tablets, based on a patient-specific prescription. Under general compounding pharmacy regulations, 503A pharmacies compound for individual patients rather than producing bulk supply, and a compounded product has not itself undergone FDA approval the way the manufactured tablet has. Anyone using a compounding pharmacy for modafinil should confirm the pharmacy holds both a current Pennsylvania Board of Pharmacy license and an active DEA registration covering Schedule IV substances, since compounded controlled substances carry additional oversight requirements.

Transferring an existing modafinil prescription to Pennsylvania

Under federal law, a Schedule IV prescription with remaining refills can generally be transferred once, pharmacy to pharmacy (not carried by the patient across state lines). If a prescription has zero refills left, a new evaluation with a Pennsylvania-licensed prescriber is required before a new prescription can be written; telehealth can often accomplish this if the patient brings records of the prior diagnosis and treatment.

Dosing, safety, and interactions clinicians consider

Individualized dosing is a decision for the prescriber, not something this article can specify for a given patient. In general terms, the FDA label describes an adult starting dose in a defined range taken in the morning for narcolepsy and OSA-related sleepiness, or shortly before a work shift for shift-work sleep disorder, with a maximum labeled daily dose; patients with significant hepatic impairment require dose adjustment per the label. Readers should review dosing specifics directly with their prescriber and the current FDA-approved prescribing information rather than a secondary source.

Clinically important points to raise with a prescriber:

• Modafinil is a CYP3A4 inducer and can reduce the effectiveness of hormonal contraceptives (pills, patches, rings); a barrier method or non-hormonal option is typically recommended during use and for a period after stopping, per the FDA label.
• The label carries precautions regarding cardiovascular effects; patients with a history of mitral valve prolapse, left ventricular hypertrophy, arrhythmia, or uncontrolled hypertension should discuss this specifically before starting.
• Modafinil is generally not recommended for patients under 17; pediatric approval was not established.
• Common side effects reported in modafinil's pivotal trials include headache, nausea, nervousness, and insomnia; a reader wanting exact incidence figures should consult the FDA label directly, since specific percentage claims require verification against the primary trial data rather than a secondhand summary.

Seek urgent care for chest pain, a fast or irregular heartbeat, signs of a serious skin reaction (blistering, peeling, mucous membrane involvement), or new mood changes such as agitation, hallucinations, or suicidal thoughts after starting modafinil.

Evidence boundary: what is established, what is not

Established: modafinil is FDA-approved for narcolepsy, OSA-related residual sleepiness, and shift-work sleep disorder; it is a federal Schedule IV controlled substance; Pennsylvania permits telehealth prescribing of Schedule IV medications after a real-time evaluation; generic modafinil has been available since patent expiration in 2012.

Plausible but not verified in this draft: exact Pennsylvania Medicaid MCO decision timelines, specific ICD-10 documentation requirements by plan, exact same-day-to-72-hour telehealth turnaround claims, and specific current cash-pay price ranges. These are the kind of details that change by plan year and pharmacy and need a live check before publication.

Not established: that modafinil is effective or approved for cognitive enhancement in healthy, non-sleep-deprived adults, or for stroke-related fatigue, as a standard of care. Research in adjacent areas exists and continues, but it does not equal an approved indication or a guarantee of insurance coverage.

Verification checklist before you rely on this page

Use this to separate facts that are stable enough to trust as written from facts that need a fresh check for your specific plan, pharmacy, and date.

Stable, unlikely to change soon (federal/clinical facts):

• Modafinil's FDA-approved indications: narcolepsy, OSA-adjunct, shift-work sleep disorder
• DEA Schedule IV classification
• Generic modafinil availability since 2012 patent expiration
• CYP3A4 induction reducing hormonal contraceptive efficacy (per FDA label)
• Basic requirement of a real-time video visit for telehealth controlled-substance prescribing

Date-sensitive, verify before acting (state, insurer, pharmacy, price facts):

• Your specific Pennsylvania Medicaid MCO's current prior authorization form and turnaround time
• Whether your commercial plan places generic modafinil on a covered tier and what the copay is
• Current cash-pay price at your specific pharmacy or discount card, as of the date you fill
• Whether your chosen telehealth platform's prescribers are currently licensed in Pennsylvania
• Current nurse practitioner or physician assistant Schedule IV prescribing scope under Pennsylvania board rules, since these are periodically updated
• Whether a specific 503A compounding pharmacy currently holds an active Pennsylvania license and DEA Schedule IV registration

If any date-sensitive item above cannot be confirmed at the time you need it, treat the corresponding claim in this article as directional, not final, and confirm directly with the payer, board, or pharmacy.

This article is a draft prepared for editorial and qualified medical review. It has not yet received clinician sign-off. Coverage rules, prescribing scope, and prices referenced above should be independently verified before publication, as noted in the checklist.